Trials / Completed
CompletedNCT00584948
Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- University of California, Davis · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Memantine | Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study. |
| DRUG | Placebo | Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2008-01-02
- Last updated
- 2017-05-30
- Results posted
- 2017-04-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00584948. Inclusion in this directory is not an endorsement.